3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
2
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gastrointestinal
1
Conditions
Multiple Myeloma
15
Leukemia, Lymphocytic, Chronic, B-Cell
10
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma, Follicular
7
Lymphoma, Non-Hodgkin
6
Burkitt Lymphoma
6
Lymphoma, Mantle-Cell
5
Lymphoma, B-Cell, Marginal Zone
5
Lymphoma
5
Astrocytoma
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Lymphoma, T-Cell, Cutaneous
3
Leukemia, Myelomonocytic, Chronic
3
Leukemia, Myelomonocytic, Acute
3
Leukemia, Myeloid, Acute
3
Hematologic Diseases
3
Waldenstrom Macroglobulinemia
2
Uveal Melanoma
2
Smoldering Multiple Myeloma
2
Sezary Syndrome
2
Optic Nerve Glioma
2
Oligodendroglioma
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large-Cell, Anaplastic
2
Leukemia, Promyelocytic, Acute
2
Interventions
Fluorouracil
70
Leucovorin
66
Oxaliplatin
50
Irinotecan
32
Cetuximab
23
Bevacizumab
20
Capecitabine
16
Chemotherapy, Adjuvant
15
Folfox protocol
13
sargramostim
7
Neoadjuvant Therapy
7
Erlotinib Hydrochloride
7
aldesleukin
5
Trastuzumab
5
Melphalan
5
Magnetic Resonance Spectroscopy
5
Gene Expression Profiling
5
Floxuridine
5
Biopsy
5
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
5
dehydroftorafur
4
Specimen Handling
4
Polymerase Chain Reaction
4
Interferon-alpha
4
Immunoglobulin G
4
Gemcitabine
4
Gefitinib
4
Disulfides
4
Cyclophosphamide
4
fludarabine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NIH
×
Colonic Neoplasms
×
Lenalidomide
×
Clear all
NCT01254617
2020-03-13
ADCC
National Cancer Institute (NCI)
Phase 1
Completed
24 enrolled